As some of you know I have just come back from a private clinic in Germany receiving some alternative treatments and while I was there I had a blood test done to see what chemotherapy, re-purposed drugs and natural infusions my specific cancer is sensitive to. The company is called Datar Cancer Genetics and the test I had done was the ‘Chemo-Scale – Chemo Sensitivity Test – Oncology Drugs + Repurposed Drugs’ but just make sure this also includes the re-purposed drugs and natural infusions too because I didn’t request this myself it was done through the clinic in Germany so I’m not sure exactly what test was requested whether this is one test or multiple tests (I just have the information when I got the results back).
So as I said in the Tik Tok video these test results are specific to my own cancer, they took my blood in a petri dish and dripped on different chemotherapy drugs, re-purposed drugs and natural infusions and saw which ones had the best results at destroying my specific cancer cells. Below are the chemotherapy drugs:
And these are the repurposed drugs and natural infusions. Iscador Qu is a brand name of Mistletoe and look there are only 4 chemotherapies that scored higher than it (and none of them are the ones I have been offered by the NHS).
So as you can see the 2 prescribed chemotherapies for ovarian cancer Carboplatin (scored only 43% for my cancer) and Paclitaxel (scored only 32%) were not as effective as Mistletoe, Vitamin C, Atorvastatin, Doxycycline, Resveratrol, Metformin, Aspirin etc all of which have much less side effects and are much less toxic than chemotherapy.
Now I’m not saying chemotherapy is not effective, I’m just saying we should be testing which (if any) chemotherapies ARE effective for each individual cancer, and also testing re-purposed less toxic drugs and natural infusions too as some of these may be even more effective than the chemotherapy with much less side effects and toxicity.
This test cost around £1600 so it wasn’t cheap, and I’m not sure if you can request it yourself or if you need to go through a health provider like I did but it is well worth looking into, especially if you are late stage and/or your cancer is not responding very well to the ‘standard of care’ treatment or they have given you a very low chance of a full remission (meaning they don’t have a solution).
Cautions
Now some cautions provided by Datar are:
1, Results of Chemo-scale test are based on in-vitro testing of cancer cells under controlled laboratory conditions and may not exactly replicate in-vivo (within the patient’s body).
2, Chemo-scale test report is not intended to be a substitute for care by a licensed healthcare professional. The information provided in this report is not a substitute for medical advice, diagnosis, treatment or a full medical evaluation. All laboratory test results must be interpreted within the context of a patient’s overall health and should be used along with other examinations or tests. Datar Cancer Genetic is not responsible for and does not accept the liability for any direct or indirect loss or damages arising from, or related to, the use of this information. This is not a prescription.
References
The references Datar has provided for this test are:
1 Akolkar DB, Crook T, Page R, Patil D, Limaye S, Datta V, et al. Liquid biopsies to enable non-invasive real-time functional chemoresistance profiling in solid organ cancers. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3525-3525.
2 Crook T, Gaya A, Page R, Limaye S, Ranade A, Bhatt A, et al. Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors. Cancer chemotherapy and pharmacology. 2021 Feb;87(2):197-205.
3 Doumat G, Daher D, Zerdan MB, Nasra N, Bahmad HF, et al. Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems. Current Oncology. 2023; 30(1):704-719.
4 Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, et al. Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions. Acta Pharmaceutica Sinica B. 2021 Sep 10.
5 Nagarkar R, Patil D, Crook T, Datta V, Bhalerao S, Dhande S, et al. Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial. Oncotarget. 2019 Sep 24;10(54):5605.
6 NCCN Clinical practice guidelines in oncology. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. 2024.
7 Ozsvári B, Lamb R, Lisanti MP. Repurposing of FDA-approved drugs against cancer – focus on metastasis. Aging (Albany NY). 2016 r;8(4):567-8.
8 Schuster S, Akolkar D, Patil S, Patil D, Datta V, Srinivasan A, et al. In vitro functional interrogation of viable circulating tumor associated cells (C-TACs) for evaluating platin resistance. Annals of Oncology. 2019 Oct 1;30:v793.